May 13, 2011 |
The Food and Drug Administration on Friday approved marketing of the Merck drug boceprevir, the first new drug for hepatitis C in 20 years. The agency is still considering approval of a similar drug, telaprevir, and is expected to approve it soon as well. Both drugs are members of a new class of hepatitis drugs called protease inhibitors, which block a key enzyme required by the virus to replicate. They are expected to convert hepatitis C from a debilitating disease into a manageable condition for the majority of people infected with the virus.
January 30, 1996 |
In some of the strongest evidence thus far that a new generation of AIDS drugs can inhibit the human immunodeficiency virus, scientists reported Monday that HIV became virtually undetectable in most patients six months after starting treatment with one of the new drugs in combination with two standard ones. "For the first time we may be close to achieving almost total suppression of the AIDS virus in most patients," said Dr.
July 4, 1996 |
For the first time since the AIDS epidemic began sweeping across America and the world, physicians think they may have the weapons to place them on an equal footing with the deadly virus. While cautious about using the word "cure," researchers gathering Sunday in Vancouver for the 11th International Conference on AIDS are optimistic that they can begin to bring the epidemic under control.
June 19, 1997 |
Federal health officials are expected to recommend today that most HIV-infected patients be treated early and aggressively with potent triple-drug combinations that include a protease inhibitor, a regimen that is not always currently practiced among clinicians nationwide.
June 5, 2004
Re "Activists Put Drug Research on Chopping Block," Commentary, June 1: I was described by James Glassman and Nick Schulz as a "left-wing activist" who is engaged in a "relentless campaign against technological innovation" spreading "Luddite nonsense that kills people." Allow me to respond. What has them riled up is Essential Inventions' petition asking the Bush administration to allow generic drug companies to use six government-funded patents relating to the AIDS drug ritonavir, sold now under the trade name Norvir.
June 5, 2011 |
Thirty years ago Sunday, a brief report in the Morbidity and Mortality Weekly Report described cases of a rare form of pneumonia called Pneumocystis carinii in five young Los Angeles men, "all active homosexuals. " The cases were noteworthy because the men had previously been healthy, though their particular pneumonia had only been seen in people with severely depressed immune systems. Within a month, a second report had identified 54 young gay men with a rare cancer known as Kaposi's sarcoma, another disease that had been almost unknown in young men. And by the following summer, the mysterious disease underlying these reports had a name: acquired immune deficiency syndrome, or AIDS.
November 5, 1996 |
On a recent Monday night at the Ron Stone HIV Center in West Hollywood, Michael Monroe is leading a class in rebirthing, sponsored by Being Alive, a support agency run by and for people with the virus. "Rebirthing" is a breathing technique that is said to help dislodge emotional blocks and ease coping with stress and fears--one of the myriad alternative therapies the HIV community assimilated during the decade when no medication worked.
January 1, 1997 |
Composer Jerry Herman, whose Broadway hits number "Hello, Dolly!," "Mame" and "La Cage aux Folles," is on a roll. His autobiography recently was published and a revue with 45 of his songs is running in San Francisco. He recently composed the score for his first TV musical, "Mrs. Santa Claus," and wrote his first children's song, for an upcoming movie about Barney, the purple dinosaur. What he wants next is a subject to turn into another Broadway musical.
June 22, 1995 |
The first of a promising but still experimental new class of AIDS drugs will be made available free to about 2,000 patients through a government-sanctioned lottery. Manufacturer Hoffman-La Roche will offer Invirase to patients in the advanced stages of AIDS who are not participating in clinical trials of the class of drugs known as protease inhibitors, which appear to be the most potent yet at reducing the amount of HIV virus in a patient's blood.
CALIFORNIA | LOCAL
March 26, 1998
A new study provides hard evidence that the powerful new AIDS drug cocktails including protease inhibitors are saving lives. Dr. Frank Palella Jr. at Northwestern University Medical School in Chicago and his colleagues analyzed data on 1,255 patients treated at nine U.S. clinics from 1994 to 1997. In 1994, they reported in today's New England Journal of Medicine, only 25% of patients were getting more than one AIDS drug.